JP2017533969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533969A5 JP2017533969A5 JP2017544552A JP2017544552A JP2017533969A5 JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5 JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017544552 A JP2017544552 A JP 2017544552A JP 2017533969 A5 JP2017533969 A5 JP 2017533969A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- naca
- agent according
- prophylactic agent
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 12
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims 11
- 241001669680 Dormitator maculatus Species 0.000 claims 10
- 230000000069 prophylactic effect Effects 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 230000006735 deficit Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229960001563 acetylcysteine amide Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076594P | 2014-11-07 | 2014-11-07 | |
| US62/076,594 | 2014-11-07 | ||
| PCT/US2015/059589 WO2016073931A1 (en) | 2014-11-07 | 2015-11-06 | Treatment of retinitis pigmentosa with n-acetylcysteine amide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Division JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017533969A JP2017533969A (ja) | 2017-11-16 |
| JP2017533969A5 true JP2017533969A5 (enExample) | 2018-04-19 |
Family
ID=55909913
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544552A Pending JP2017533969A (ja) | 2014-11-07 | 2015-11-06 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019191044A Pending JP2020023549A (ja) | 2014-11-07 | 2019-10-18 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2021147283A Pending JP2021193119A (ja) | 2014-11-07 | 2021-09-10 | Ｎ−アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2023127716A Pending JP2023145734A (ja) | 2014-11-07 | 2023-08-04 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
| JP2025126989A Pending JP2025160381A (ja) | 2014-11-07 | 2025-07-30 | Ｎ－アセチルシステインアミドによる網膜色素変性症の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180296503A1 (enExample) |
| EP (2) | EP3214934A4 (enExample) |
| JP (5) | JP2017533969A (enExample) |
| KR (3) | KR20230152177A (enExample) |
| CN (2) | CN107426997A (enExample) |
| AU (4) | AU2015342831B2 (enExample) |
| BR (1) | BR112017009584A2 (enExample) |
| CA (1) | CA2967327C (enExample) |
| HK (1) | HK1252822A1 (enExample) |
| RU (1) | RU2711913C2 (enExample) |
| WO (2) | WO2016073931A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10752593B2 (en) | 2018-12-28 | 2020-08-25 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| RU2711913C2 (ru) | 2014-11-07 | 2020-01-24 | Дзе Джонс Хопкинс Юниверсити | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| US11548851B2 (en) | 2017-09-20 | 2023-01-10 | Nacuity Pharmaceuticals, Inc. | Method for preparation of n-acetyl cysteine amide and derivatives thereof |
| US11091433B2 (en) | 2017-09-20 | 2021-08-17 | Nacuity Pharmaceutials, Inc. | Method for preparation of N-acetyl cysteine amide and derivatives thereof |
| US20190135741A1 (en) * | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| US20190151271A1 (en) * | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| WO2020011607A1 (en) * | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
| CN109096161B (zh) * | 2018-08-24 | 2020-10-27 | 武汉远大弘元股份有限公司 | 一种n-乙酰半胱氨酸的制备方法 |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
| US12245998B2 (en) | 2019-01-11 | 2025-03-11 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| WO2021151044A1 (en) * | 2020-01-24 | 2021-07-29 | Nacuity Pharmaceuticals, Inc. | Prodrug for the treatment of disease and injury of oxidative stress |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3340147A (en) | 1965-06-28 | 1967-09-05 | Mead Johnson & Co | Amides of n-acylated cysteines |
| US5874468A (en) | 1996-12-26 | 1999-02-23 | Yissum | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| WO2002100293A2 (en) | 2001-06-13 | 2002-12-19 | Webb-Waring Institute For Biomedical Research | A diagnostic and prognostic method for evaluating ocular inflammation and oxidative stress and the treatment of the same |
| BE1014949A3 (fr) | 2001-08-14 | 2004-07-06 | Probiox | Procede de detection de stress oxydant et trousse pour sa mise en oeuvre. |
| WO2004012652A2 (en) | 2002-08-02 | 2004-02-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| WO2004028536A1 (en) | 2002-09-30 | 2004-04-08 | Babizhayev Mark A | Method for topical treatment of eye disease and composition and device for said treatment |
| JP2005350405A (ja) | 2004-06-11 | 2005-12-22 | Shiseido Co Ltd | 重合抑制剤および即時型黒化防止用皮膚外用剤 |
| US8993627B2 (en) | 2005-04-21 | 2015-03-31 | Sentient Lifesciences, Inc. | N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress |
| KR20080028357A (ko) | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드) |
| CN101232877A (zh) * | 2005-04-21 | 2008-07-30 | 格伦·A·戈尔茨坦 | 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺） |
| JP4840804B2 (ja) | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| WO2010048716A1 (en) | 2008-10-29 | 2010-05-06 | Pacific Therapeutics Ltd. | Composition and method for treating fibrosis |
| US20120150029A1 (en) | 2008-12-19 | 2012-06-14 | University Of Miami | System and Method for Detection and Monitoring of Ocular Diseases and Disorders using Optical Coherence Tomography |
| US9173423B2 (en) | 2009-07-31 | 2015-11-03 | The Iams Company | Animal food kibble with electrostatically adhered dusting |
| WO2011044230A2 (en) | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| US20120142550A1 (en) | 2010-12-06 | 2012-06-07 | Zehnder James L | Vanin 1 as a Peripheral Blood Oxidative Stress Sensor |
| WO2013138744A1 (en) | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| US20150148423A1 (en) * | 2012-04-26 | 2015-05-28 | Sentient Lifesciences, Inc. | Use of n-acetylcysteine amide in the treatment of disease and injury |
| WO2014088631A1 (en) | 2012-12-06 | 2014-06-12 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
| US20150328337A1 (en) | 2012-12-19 | 2015-11-19 | The Johns Hopkins University | Protection from oxidative damage by gene transfer by glutamate cysteine ligase and glutathione synthase |
| EP3122342B1 (en) | 2014-03-28 | 2020-09-23 | NaCuity Pharmaceuticals, Inc. | Method for the preparation of n-acetyl cysteine amide |
| RU2711913C2 (ru) | 2014-11-07 | 2020-01-24 | Дзе Джонс Хопкинс Юниверсити | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом |
| US11268964B2 (en) | 2014-11-11 | 2022-03-08 | The Johns Hopkins University | Biomarkers useful in the treatment of subjects having diseases of the eye |
| US11173135B2 (en) | 2016-03-17 | 2021-11-16 | Thiogenesis Therapeutics, Inc. | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders |
| CN111386255B (zh) | 2017-09-20 | 2021-11-23 | 纳崔泰制药有限公司 | 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法 |
| CN118924717A (zh) | 2017-09-20 | 2024-11-12 | 硫创治疗公司 | 用于治疗半胱胺敏感性病症的方法 |
| WO2019060704A1 (en) | 2017-09-22 | 2019-03-28 | University Of Florida Research Foundation | DEVICES AND METHODS FOR REDUCTION OF IN VIVO CYSTINE CRYSTALS |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2019097434A1 (en) | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| US20190151271A1 (en) | 2017-11-21 | 2019-05-23 | The Johns Hopkins University | Compositions and methods for treatment of eye diseases |
| CN108618993B (zh) | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
| US20210369649A1 (en) | 2018-11-16 | 2021-12-02 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Thermoresponsive gel eye drop for ocular delivery of cysteamine |
| US12245998B2 (en) | 2019-01-11 | 2025-03-11 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (NACA) and (2R,2R′)-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis |
| US12458608B2 (en) | 2019-01-11 | 2025-11-04 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
| US11766413B2 (en) | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
-
2015
- 2015-11-06 RU RU2017119230A patent/RU2711913C2/ru active
- 2015-11-06 US US15/524,636 patent/US20180296503A1/en not_active Abandoned
- 2015-11-06 KR KR1020237036499A patent/KR20230152177A/ko active Pending
- 2015-11-06 KR KR1020177015227A patent/KR20170109527A/ko not_active Ceased
- 2015-11-06 KR KR1020227009489A patent/KR20220039853A/ko not_active Ceased
- 2015-11-06 AU AU2015342831A patent/AU2015342831B2/en active Active
- 2015-11-06 BR BR112017009584A patent/BR112017009584A2/pt not_active Application Discontinuation
- 2015-11-06 CN CN201580072224.6A patent/CN107426997A/zh active Pending
- 2015-11-06 US US15/523,665 patent/US12472157B2/en active Active
- 2015-11-06 WO PCT/US2015/059589 patent/WO2016073931A1/en not_active Ceased
- 2015-11-06 CA CA2967327A patent/CA2967327C/en active Active
- 2015-11-06 EP EP15857309.7A patent/EP3214934A4/en not_active Ceased
- 2015-11-06 EP EP21217485.8A patent/EP4000612A1/en active Pending
- 2015-11-06 CN CN201810698779.7A patent/CN108498495A/zh active Pending
- 2015-11-06 JP JP2017544552A patent/JP2017533969A/ja active Pending
- 2015-11-06 WO PCT/US2015/059418 patent/WO2016073829A2/en not_active Ceased
-
2018
- 2018-09-20 HK HK18112150.1A patent/HK1252822A1/zh unknown
-
2019
- 2019-10-18 JP JP2019191044A patent/JP2020023549A/ja active Pending
- 2019-11-07 AU AU2019261762A patent/AU2019261762B2/en active Active
-
2021
- 2021-09-06 AU AU2021225263A patent/AU2021225263B2/en active Active
- 2021-09-10 JP JP2021147283A patent/JP2021193119A/ja active Pending
-
2023
- 2023-08-04 JP JP2023127716A patent/JP2023145734A/ja active Pending
-
2024
- 2024-01-24 AU AU2024200436A patent/AU2024200436A1/en active Pending
-
2025
- 2025-07-30 JP JP2025126989A patent/JP2025160381A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533969A5 (enExample) | ||
| JP2020023549A5 (enExample) | ||
| JP2023145734A5 (enExample) | ||
| RU2017119230A (ru) | Лечение пигментной дистрофии сетчатки n-ацетилцистеинамидом | |
| NZ605888A (en) | Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| MX2020014000A (es) | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. | |
| RU2009148288A (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
| AU2012284627A8 (en) | Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans | |
| IN2014MN01706A (enExample) | ||
| JP2015038135A5 (enExample) | ||
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| RU2010147287A (ru) | Комбинированная композиция | |
| JP2017506624A5 (enExample) | ||
| MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
| MX2010003441A (es) | Formulaciones galenicas de alisquireno y valsartan. | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| ME02474B (me) | Terapijski režimi | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| MX2023001014A (es) | Composiciones farmaceuticas que comprenden venglustat. | |
| RU2020123405A (ru) | Лекарственная композиция для профилактики или лечения вторичного гиперпаратиреоза при поддерживающем диализе | |
| WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
| NZ751972A (en) | Treatment of prurigo nodularis | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin |